Suspected limited efficacy of γ-secretase modulators

Neurobiology of Aging

Volumn 34, Issue 4, 2013, Pages 1101-1104

  Kakuda, Nobuto ^a,b   Akazawa, Kohei ^c   Hatsuta, Hiroyuki ^d   Murayama, Shigeo ^d   Ihara, Yasuo ^a,b,e  

^a DOSHISHA UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^e NEW ENERGY AND INDUSTRIAL TECHNOLOGY DEVELOPMENT ORGANIZATION   (Japan)

Author keywords

Modulator; Secretase; Alzheimer's disease

Indexed keywords

AGENTS AFFECTING METABOLISM; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN 43; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PROTEIN; GAMMA SECRETASE MODULATOR 1; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; NEUROMODULATION; PRIORITY JOURNAL; PROTEIN METABOLISM;

AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; BRAIN CHEMISTRY; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; HUMANS; MALE;

EID: 84872307904     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.08.017     Document Type: Article

References (17)

1. Borgegard T., Juréus A., Olsson F., Rosqvist S., Sabirsh A., Rotticci D., Paulsen K., Klintenberg R., Yan H., Waldman M., Stromberg K., Nord J., Johansson J., Regner A., Parpal S., Malinowsky D., Radesater A.C., Li T., Singh R., Eriksson H., Lundkvist J. First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms. J. Biol. Chem. 2012, 287:11810-11819.
2. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
3. Crump C.J., Fish B.A., Castro S.V., Chau D.M., Gertsik N., Ahn K., Stiff C., Pozdnyakov N., Bales K.R., Johnson D.S., Li Y.M. Piperidine acetic acid based γ-secretase modulators directly bind to Presenilin-1. ACS Chem. Neurosci. 2011, 2:705-710.
4. Duyckaerts C., Hauw J.J. Prevalence, incidence and duration of Braak's stages in the general population: can we know?. Neurobiol. Aging 1997, 18:362-369.
5. Ebke A., Luebbers T., Fukumori A., Shirotani K., Haass C., Baumann K., Steiner H. Novel γ-secretase enzyme modulators directly target presenilin protein. J. Biol. Chem. 2011, 286:37181-37186.
6. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
7. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of Aβ42(43) and Aβ40 in senile plaque with end-specific Aβ monoclonals: evidence that an initially deposited forms is Aβ42(43). Neuron 1994, 13:45-53.
8. Kakuda N., Shoji M., Arai H., Furukawa K., Ikeuchi T., Akazawa K., Takami M., Hatsuta H., Murayama S., Hashimoto Y., Miyajima M., Arai H., Nagashima Y., Yamaguchi H., Kuwano R., Nagaike K., Ihara Y., Japanese Alzheimer's Disease Neuroimaging Initiative Altered γ-secretase activity in mild cognitive impairment and Alzheimer's disease. EMBO Mol. Med. 2012, 4:344-352.
9. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (β) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21:372-381.
10. Kounnas M.Z., Danks A.M., Cheng S., Tyree C., Ackerman E., Zhang X., Ahn K., Nguyen P., Comer D., Mao L., Yu C., Pleynet D., Digregorio P.J., Velicelebi G., Stauderman K.A., Comer W.T., Mobley W.C., Li Y.M., Sisodia S.S., Tanzi R.E., Wagner S.L. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010, 67:769-780.
11. Ohki Y., Higo T., Uemura K., Shimada N., Osawa S., Berezovska O., Yokoshima S., Fukuyama T., Tomita T., Iwatsubo T. Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1. EMBO J. 2011, 30:4815-4824.
12. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
13. Serneels L., Van Biervliet J., Craessaerts K., Dejaegere T., Horré K., Van Houtvin T., Esselmann H., Paul S., Schäfer M.K., Berezovska O., Hyman B.T., Sprangers B., Sciot R., Moons L., Jucker M., Yang Z., May P.C., Karran E., Wiltfang J., D'Hooge R., De Strooper B. γ-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 2009, 324:639-642.
14. Sisodia S.S., St George-Hyslop P.H. gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?. Nat. Rev. Neurosci. 2002, 3:281-290.
15. Takami M., Nagashima Y., Sano Y., Ishihara S., Morishima-Kawashima M., Funamoto S., Ihara Y. γ-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of β-carboxyl terminal fragment. J. Neurosci. 2009, 29:13042-13052.
16. Takasugi N., Tomita T., Hayashi I., Tsuruoka M., Niimura M., Takahashi Y., Thinakaran G., Iwatsubo T. The role of presenilin cofactors in the γ-secretase complex. Nature 2003, 422:438-441.
17. Wakabayashi T., De Strooper B. Presenilins: members of the gamma-secretase quartets, but part-time soloists too. J. Physiol. 2008, 23:194-204.